Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis
NCT ID: NCT06477536
Last Updated: 2025-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
33 participants
INTERVENTIONAL
2024-09-02
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of HB0034 in Patients with Generalized Pustular Psoriasis (GPP)
NCT06231381
HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
NCT05512598
A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
NCT05531682
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
NCT06477237
A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic Dermatitis
NCT07330934
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HB0034
single-arm and all the patients would receive HB0034 300mg i.v. every other four weeks
HB0034
300mg, i.v. Q4W
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
HB0034
300mg, i.v. Q4W
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment
* Men and women of reproductive age who have no parenting plans and are willing to use reliable contraception during the study period and for 6 months after the last dose of the study drug;
* Patients who fully understand and voluntarily sign an ICF, and are willing and able to follow clinical study and subsequent visit schedules
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Huaota Biopharmaceutical Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jianzhong Zhang, PhD
Role: PRINCIPAL_INVESTIGATOR
Peking University People's Hospital (PKUPH)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital (PKUPH)
Beijing, , China
Peking University People's Hospital
Beijing, , China
The Second affiliated Hospital zhejiang University School of Medicine
Hangzhou, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HB0034-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.